Sharkey Robert M, Sausville Edward A, Goldenberg David M
Center for Molecular Medicine and Immunology, Garden State Cancer Center, 520 Belleville Avenue, Belleville, NJ 07945, USA.
Cancer Res. 2003 Nov 15;63(22):8069-71.
This conference, held biennially for the past 12 years, provides a forum where investigators from throughout the world can gather and discuss how monoclonal antibodies can be used to improve the treatment of cancer. As in the past, this meeting focused primarily on the use of radiolabeled antibodies in cancer treatment, but this year there were many additional contributions on the use of unconjugated "naked" antibodies for the treatment of cancer, reflecting a growing understanding that antibodies not only can be used to direct isotopes and drugs to tumors but can also be effective agents in themselves. Preclinical studies using immunoconjugates prepared with toxins, drugs, or other agents were also reported to be highly effective therapeutic agents. Some of these are now showing efficacy in clinical trials. In addition, presentations focused on a variety of approaches, including pretargeting, regional delivery, and combinations with other standard treatment regimens designed to optimize antibody-targeted treatment strategies. Although the most efficacious treatments were reported in a variety of hematological malignancies, there were a number of presentations, primarily in early preclinical development, that provided evidence for potential future improvements in the treatment of solid tumors.
在过去12年里，该会议每两年举办一次，为来自世界各地的研究人员提供了一个交流平台，探讨如何利用单克隆抗体改善癌症治疗。与以往一样，本次会议主要聚焦于放射性标记抗体在癌症治疗中的应用，但今年有许多关于使用未偶联“裸”抗体治疗癌症的额外报告，这反映出人们越来越认识到抗体不仅可用于将同位素和药物导向肿瘤，自身也可以是有效的治疗药物。据报道，使用毒素、药物或其他制剂制备的免疫偶联物进行的临床前研究也是高效的治疗药物。其中一些目前在临床试验中显示出疗效。此外，报告还聚焦于多种方法，包括预靶向、区域给药以及与其他标准治疗方案联合，旨在优化抗体靶向治疗策略。尽管在多种血液系统恶性肿瘤中报告了最有效的治疗方法，但也有一些报告（主要处于临床前早期开发阶段）为未来实体瘤治疗的潜在改善提供了证据。
